280
Views
3
CrossRef citations to date
0
Altmetric
Letter to the Editor

Rubinstein–Taybi syndrome – a window into follicular lymphoma biology

, &
Pages 2908-2910 | Received 15 Jan 2016, Accepted 06 Mar 2016, Published online: 18 Apr 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Koorosh Korfi, Sara Ali, James A. Heward & Jude Fitzgibbon. (2017) Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations. Epigenetics 12:5, pages 370-377.
Read now

Articles from other publishers (2)

Francesco Saettini, Richard Herriot, Elisabetta Prada, Mathilde Nizon, Daniele Zama, Antonio Marzollo, Igor Romaniouk, Vassilios Lougaris, Manuela Cortesi, Alessia Morreale, Rika Kosaki, Fabio Cardinale, Silvia Ricci, Elena Domínguez-Garrido, Davide Montin, Marie Vincent, Donatella Milani, Andrea Biondi, Cristina Gervasini & Raffaele Badolato. (2020) Prevalence of Immunological Defects in a Cohort of 97 Rubinstein–Taybi Syndrome Patients. Journal of Clinical Immunology 40:6, pages 851-860.
Crossref
Max V. Boot, Martine J. van Belzen, Lucy I. Overbeek, Nathalie Hijmering, Matias Mendeville, Quinten Waisfisz, Pieter Wesseling, Raoul C. Hennekam & Daphne de Jong. (2018) Benign and malignant tumors in Rubinstein–Taybi syndrome. American Journal of Medical Genetics Part A 176:3, pages 597-608.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.